TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07209761: A Phase 3, Randomized, Open-label, Multicenter Trial to Evaluate the Efficacy, Safety, and Tolerability of 4-month and 6-month Quabodepistat-containing Regimens for Rifampicin-resistant/Multidrug-resistant Pulmonary Tube

Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. · Phase: PHASE3 · Area: INFECTIOUS_VACCINE · Target Enrollment: 532 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$8,516,592

Rescue Site Savings

+$5,635,980

Unlock Full NCT07209761 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07209761 Rescue Dossier →